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ABSTRACT
Objective Earlier detection of pulmonary arterial
hypertension (PAH), a leading cause of death in systemic
sclerosis (SSc), facilitates earlier treatment. The objective
of this study was to develop the ﬁrst evidence-based
detection algorithm for PAH in SSc.
Methods In this cross-sectional, international study
conducted in 62 experienced centres from North
America, Europe and Asia, adults with SSc at increased
risk of PAH (SSc for >3 years and predicted pulmonary
diffusing capacity for carbon monoxide <60%)
underwent a broad panel of non-invasive assessments
followed by diagnostic right heart catheterisation (RHC).
Univariable and multivariable analyses selected the best
discriminatory variables for identifying PAH. After
assessment for clinical plausibility and feasibility, these
were incorporated into a two-step, internally validated
detection algorithm. Nomograms for clinical practice use
were developed.
Results Of 466 SSc patients at increased risk of PAH,
87 (19%) had RHC-conﬁrmed PAH. PAH was mild (64%
in WHO functional class I/II). Six simple assessments in
Step 1 of the algorithm determined referral to
echocardiography. In Step 2, the Step 1 prediction score
and two echocardiographic variables determined referral
to RHC. The DETECT algorithm recommended RHC in
62% of patients (referral rate) and missed 4% of PAH
patients (false negatives). By comparison, applying
European Society of Cardiology/European Respiratory
Society guidelines to these patients, 29% of diagnoses
were missed while requiring an RHC referral rate of
40%.
Conclusions The novel, evidence-based DETECT
algorithm for PAH detection in SSc is a sensitive, non-
invasive tool which minimises missed diagnoses,
identiﬁes milder disease and addresses resource usage.
INTRODUCTION
The diagnosis of pulmonary arterial hypertension
(PAH) is deﬁned at right heart catheterisation
(RHC) by a mean pulmonary arterial pressure
(mPAP) of ≥25 mm Hg with a pulmonary capillary
wedge pressure (PCWP) of ≤15 mm Hg.1
Additional diagnostic criteria may include a normal
or reduced cardiac output1 or a pulmonary vascular
resistance (PVR) of >3 Wood units.2 PAH includes
diverse clinical phenotypes, prominent among
which is systemic sclerosis (SSc, scleroderma) where
PAH has emerged as a leading cause of death.3 4
Three-year survival for SSc patients with PAH has
been estimated to be 56% compared with 94% in
those without PAH.5 Observational studies have
demonstrated that mortality remains high in SSc
patients with PAH despite current best therapy.6 7
Poor outcome of PAH in SSc may be partially
explained by disease-related comorbidities but also
by delay in diagnosis. One recent study observed a
better prognosis in subjects identiﬁed in an active
screening programme compared with those identi-
ﬁed in the course of routine practice,8 suggesting
potential beneﬁt of intervention earlier in the
course of disease. This is consistent with the beneﬁ-
cial treatment effects demonstrated in early PAH.9
Current screening recommendations are largely
based on consensus.1 2 Several organisations,
including the American College of Cardiology
Foundation/American Heart Association and the
European Society of Cardiology/European
Respiratory Society (ESC/ERS), have published a
variety of screening recommendations relying
mainly on symptoms and abnormal ﬁndings on
transthoracic echocardiography.1 2 10 Other clinical
tools include N-terminal probrain natriuretic
peptide (NTproBNP) as a marker of myocardial
stress,11 and disproportionately reduced pulmonary
diffusing capacity for carbon monoxide
(DLCO).12–14 The most widely used echocardio-
graphic parameter, tricuspid regurgitant jet (TR)
velocity, does not accurately reﬂect invasive pres-
sures and is not present in all patients.15 16
Furthermore, while TR velocity recommendations
are very speciﬁc in current guidelines, recommen-
dations regarding other evidence of PAH (eg, symp-
toms) are less detailed; thus, application is likely to
be variable between clinicians. More importantly,
no previous screening studies have systematically
performed RHC in all patients, precluding assess-
ment of the rate of missed diagnoses (false
negatives).
Our study provides evidence-based data guided
by the principles of screening17: (A) employing
rigorous methodology using the appropriate cross-
sectional study design in order to determine the
performance characteristics of the screening algo-
rithm (sensitivity, speciﬁcity, etc); (B) evaluating
accessible and feasible real-world screening tools;
(C) identifying patients during an asymptomatic
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phase of disease (the SSc population in this study has symptoms
which are not PAH speciﬁc) and (D) identifying patients for
whom subsequent management is appropriate. Using the anchor
of systematic RHC, the objective of the DETECT study was to
develop a detection algorithm for PAH in SSc patients that
would minimise the number of missed PAH diagnoses, while
optimising the use of diagnostic RHC.
METHODS
Study design
DETECTwas designed as a cross-sectional study in which RHC
and echocardiography were systematically conducted according
to standardised procedures. Serum laboratory testing and data
management were performed centrally, and data quality was
rigorously monitored. DETECT was conducted in accordance
with the Declaration of Helsinki and its amendments, followed
the International Conference on Harmonisation Guideline for
Good Clinical Practice, and was approved by local institutional
review boards/ethics committees. All patients provided written
informed consent.
Study population
Sixty-two experienced centres (managing at least 40 SSc
patients) from 18 countries in North America, Europe and Asia
participated in the study between 2008 and 2011. Patients aged
≥18 years with a diagnosis of SSc (American College of
Rheumatology criteria,18 including patients with other connect-
ive tissue diseases who met these criteria) of >3 years’ duration
from ﬁrst non-Raynaud’s symptom and a predicted DLCO of
<60% (to enrich for a higher likelihood of PAH), were
included. Patients were excluded if they had pulmonary hyper-
tension (PH) conﬁrmed by RHC prior to enrolment, were
receiving recognised advanced PH therapy, had a forced vital
capacity (FVC) <40% of predicted, renal insufﬁciency, previous
evidence of clinically relevant left heart disease, or were
pregnant.
Patients were classiﬁed as either non-PH, or WHO group 1
PH (PAH), WHO group 2 PH (PH due to left heart disease), or
WHO group 3 PH (PH due to lung disease/hypoxia), according
to current guidelines.10 19 WHO group 3 deﬁnition was based
on Study Scientiﬁc Committee consensus applying a conserva-
tive interpretation of the literature to minimise misclassiﬁcation
of patients with evident lung disease as PAH. Classiﬁcation deﬁ-
nitions are summarised in ﬁgure 1.
Data collection and analysis
A broad range of variables potentially associated with PAH in
SSc were assessed (112 in total; see online supplementary text).
Four groups of variables were: (A) standard demographic and
clinical parameters (68 variables in total, eg, SSc disease dur-
ation from ﬁrst non-Raynaud’s symptom, SSc subtype, SSc
symptoms and organ involvement, general medical history,
standard physical examination, 6-min walk distance, standard
pulmonary function tests); (B) serum tests analysed by a central
laboratory (antinuclear antibody proﬁle (ﬁve antibodies),
NTproBNP, endothelin-1, von Willebrand factor antigen,
C-reactive protein, serum urate, creatinine, erythrocyte sedimen-
tation rate, estimated glomerular ﬁltration rate); (C) electrocar-
diography (ECG; right ventricular strain, right axis deviation,
right bundle branch block) and (D) echocardiography according
to standardised procedures (28 variables in total, eg, right
atrium (RA) area, right ventricle (RV) area, RA diameter, TR vel-
ocity, tricuspid annular plane systolic excursion). To minimise
bias, RHC as the conﬁrmatory diagnostic test (conducted
according to standardised procedures), was performed in all
patients following collection of aforementioned data. Serious
adverse events related to any study-mandated procedure (eg,
RHC) were collected.
Statistical methodology
It was planned to enrol approximately 500 SSc patients includ-
ing the planned number of 70 patients testing positive for PAH.
This planned sample size took into consideration feasibility
aspects of the study and assumed a prevalence rate of 14%.11
This sample size was calculated to allow an estimation of 90%
sensitivity of the detection algorithm with a precision of
±7.5%. At a similar level of expected speciﬁcity, its precision is
superior, due to the higher prevalence of non-PAH.
PAH and non-PH groups were described using summary sta-
tistics; sample size, mean, SD, median, upper and lower quar-
tiles, minimum and maximum, and 95% CIs of the mean and
median for quantitative data and frequencies (counts and per-
centages) for qualitative and categorical data.
Logistic regression modelling was the main analytical method,
including linear and non-linear functional relations, where the
binary outcome variable was PAH versus non-PH. Model-building
entailed use of statistical procedures; variable selection was
informed by clinical judgement and internal validation of models
was performed via the bootstrap method.
Statistical analysis for selecting predictive variables and devel-
oping the detection algorithm for risk prediction of PAH was
performed stepwise in three broad stages (see online supplemen-
tary text, tables S2–S5 and ﬁgures S1 and S2): (A) univariable
and multivariable logistic regression models with RHC-based
classiﬁcation of PAH outcome, were applied within each of the
four above-mentioned groups of candidate variables to select
those associated with PAH; (B) the selected variables were
further reduced across groups by using multivariable logistic
regression; using nominal group technique, the Study Scientiﬁc
Committee excluded some variables based on lack of clinical
plausibility and/or feasibility with particular regard to resource
limitations in standard practice and (C) a two-step decision tree
was constructed based on two multivariable logistic regression
models. The ﬁrst step (sensitivity set at 97%) of the decision
tree included non-echocardiographic tests to produce a risk pre-
diction score that allowed exclusion of patients at low risk of
having PAH and determined referral to echocardiography for
the other patients. In the second step (speciﬁcity set at 35%),
the risk score from Step 1 was combined with echocardio-
graphic tests to produce the ﬁnal PAH risk prediction score to
determine if a patient should be referred to RHC for diagnosis.
Spline functions with three knots were used in the models to
adequately address non-linear relationships, which were initially
identiﬁed by quadratic functions during the model-building
process. Discriminatory performance to distinguish between
PAH and non-PH patients was examined by receiver operating
characteristic (ROC) curve analysis. The ROC area under the
curve (AUC) formed the criterion for assessing the discrimin-
atory ability of a model. Nomograms20 were derived from the
two multivariable risk prediction models (see online supplemen-
tary text) to allow classiﬁcation of patients into risk sets for
referral to echocardiography (Step 1) and RHC (Step 2). An
alternative algorithm with 65% speciﬁcity set in the second step
was also evaluated, as was the application of the ESC/ERS
guidelines to the DETECT population.1 The performance mea-
sures of the decision tree and its internal validation using boot-
strap methodology are described in detail in the online
supplementary text and tables S8–S11.
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RESULTS
Of 646 SSc patients screened, 158 did not meet the eligibility
criteria (mostly due to DLCO values ≥60% of predicted). Of
the 488 patients enrolled, 466 underwent RHC which revealed
PH in 31% of patients (n=145) and PAH (WHO group 1 PH)
in 19% (n=87; ﬁgure 1). Our results focus on these 87 PAH
patients versus the 321 non-PH patients.
Patient characteristics, including RHC ﬁndings, are sum-
marised in table 1.
In most patients (64%), PAH was mild (WHO functional
class I or II), with moderately elevated mPAP and pulmonary
vascular resistance and preserved mean cardiac index. In this
population, among other variables, exercise capacity on 6-min
walk test and dyspnoea were not associated with the presence of
PAH. However, compared with non-PH patients, PAH patients
were older, more likely to be male, in higher (more severe)
WHO functional class, more likely to have the limited cutane-
ous form of SSc, to be anticentromere antibody (ACA) positive
and to have a history of telangiectasias, had worse gas transfer
(as assessed by DLCO), higher serum urate and NTproBNP
levels, were more likely to have a right ventricular strain and
right axis deviation on ECG, had larger RA and RV areas and
higher TR velocity. However, when analysing commonly advo-
cated TR velocity thresholds for PAH suspicion,1 21 20% of
PAH patients were found to have a TR velocity of <2.5 m/s,
36% had a TR velocity of ≤2.8 m/s, and 63% had a TR velocity
of ≤3.4 m/s (including 7% of PAH patients with undetectable
TR velocity). Within the total DETECT cohort, 49% had a TR
velocity of <2.5 m/s (including 13% with undetectable TR vel-
ocity). Several other echocardiographic variables (eg, tricuspid
annular plane systolic excursion) were associated with the pres-
ence of PAH but did not progress to the ﬁnal model (see
below).
Following univariable and multivariable analyses, and clinical
judgment of the Study Scientiﬁc Committee (based on feasibility
and clinical plausibility), from an initial 112 variables, 13 were
selected based on their discriminatory ability to detect PAH (see
online supplementary text and table S3). These formed the basis
for constructing a detection algorithm. To align the algorithm
with real-world practice where the rheumatologist accesses
Figure 1 Patient disposition. The results reported here focus on the 408 SSc patients with PAH (n=87) and those without PH (n=321; grey boxes).
*One patient could not be assigned to a PH group due to a missing PCWP value. FVC, forced vital capacity; HRCT, high-resolution CT; mPAP, mean
pulmonary arterial pressure; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; PCWP, pulmonary capillary wedge pressure; RHC,
right heart catheterisation; SSc, systemic sclerosis.
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Table 1 Patient characteristics
Non-PH group (N=321) PAH group (N=87)
Demographics
Male, n/N (%) 53/320 (16.6) 22/86 (25.6)
Age (years), mean (SD) 54.7 (11.8) 61.1 (9.8)
Caucasian, n/N (%) 258/319 (80.9) 81/87 (93.1)
Body mass index (kg/m2), n 317 86
Mean (SD) 25.2 (5.6) 26.1 (5.5)
SSc characteristics
SSc duration* (months), n 319 87
Mean (SD) 130.2 (96.1) 163.0 (130.3)
SSc subtype, n/N (%)
Diffuse 115/315 (36.5) 18/86 (20.9)
Limited 171/315 (54.3) 61/86 (70.9)
Mixed/overlap 29/315 (9.2) 7/86 (8.1)
Current/past telangiectasias, n/N (%) 218/321 (67.9) 76/87 (87.4)
Functional capacity
6-min walk distance (m), n 243 66
Mean (SD) 412.5 (107.2) 389.7 (106.6)
Borg dyspnoea index, n 240 66
Mean (SD) 2.6 (1.8) 3.1 (2.1)
WHO functional class, n 306 87
I/II/III/IV, n (%) 133 (43.5)/123 (40.2)/50 (16.3)/0 16 (18.4)/40 (46.0)/30 (34.5)/1 (1.1)
Pulmonary function tests, n 321 87
DLCO % predicted
Mean (SD) 48.0 (9.2) 43.3 (10.5)
FVC % predicted/DLCO % predicted
Mean (SD) 1.8 (0.5) 2.2 (0.7)
Serum markers, n 306 80
NTproBNP (pg/ml)
Mean (SD) 230.0 (538.6) 516.4 (805.0)
Serum urate (mg/100 ml)
Mean (SD) 4.7 (1.5) 5.9 (1.5)
ACA positive, n/N (%) 77/306 (25.2) 40/80 (50.0)
Electrocardiography, n/N (%)
Right ventricular strain present 7/291 (2.4) 12/83 (14.5)
Right axis deviation† present 10/291 (3.4) 11/83 (13.3)
Echocardiography
Right atrium area (cm2), n 286 82
Mean (SD) 13.4 (4.7) 17.1 (6.2)
Right ventricle area (cm2), n 291 82
Mean (SD) 15.0 (5.4) 19.3 (6.8)
TR velocity (m/s), n 255 78
Mean (SD) 2.4 (0.5) 3.1 (0.7)
TR velocity (m/s), n/N (%)
‘No TR’ ticked 48/303 (15.8) 6/84 (7.1)
≤2.8 214/303 (70.6) 30/84 (35.7)
>2.8 to ≤3.4 37/303 (12.2) 23/84 (27.4)
>3.4 4/303 (1.3) 25/84 (29.8)
Haemodynamics on right heart catheterisation
mPAP (mm Hg), n 321 87
Mean (SD) 17.6 (3.8) 32.5 (8.3)
PCWP (mm Hg), n 318 87
Mean (SD) 8.5 (3.6) 10.3 (3.2)
PVR (dyn·sec/cm5), n 318 87
Mean (SD) 145.4 (64.6) 370.6 (225.8)
Cardiac index (l/min/m2), n 317 86
Mean (SD) 3.0 (0.7) 2.9 (0.6)
*From date of first non-Raynaud’s symptom.
†QRS axis ≥90°.
ACA, anticentromere antibody; DLCO, pulmonary diffusing capacity for carbon monoxide; FVC, forced vital capacity; mPAP, mean pulmonary arterial pressure; NTproBNP, N-terminal
probrain natriuretic peptide; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; SSc,
systemic sclerosis; TR, tricuspid regurgitant jet.
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non-echocardiographic data prior to referral to a cardiologist for
echocardiography, the 13 variables were divided into nine
non-echocardiographic variables (candidate variables in Step 1 of
the algorithm) and four echocardiographic variables (candidate
variables in Step 2). Subsequent multivariable analysis (stepwise
forward procedure) resulted in six simple assessments being
included in Step 1 of the algorithm to determine the need for
referral to echocardiography (table 2). These were: FVC % pre-
dicted/DLCO % predicted, current/past telangiectasias, serum
ACA, serum NTproBNP, serum urate and right axis deviation on
ECG. Two echocardiographic variables (RA area and TR velocity)
were included in Step 2 in order to determine the need for refer-
ral for RHC. Additionally, Step 2 included the carried-forward
Step 1 risk prediction score (risk points) (table 2). Of all statistic-
ally selected ﬁnal variables, the Study Scientiﬁc Committee
replaced one echocardiographic variable (RV area) with another
(RA area), because the latter is regarded as easier to assess and
likely to be more reproducible. This replacement had a minimal
effect on the performance of the Step 2 model (AUC 89% and
88% using RV area and RA area, respectively). The multivariable
logistic regression models for the two-step decision tree are sum-
marised in table 2.
Sensitivity (97% in Step 1) and speciﬁcity (35% in Step 2)
were selected by the Study Scientiﬁc Committee with the aim of
minimising the number of missed PAH diagnoses. The perform-
ance of the resulting DETECTalgorithm is presented in ﬁgure 2,
and a nomogram of the DETECT algorithm for use in clinical
practice is shown in ﬁgure 3. Internal bootstrap validation gener-
ated consistent results and conﬁrmed overall performance of the
algorithm (see online supplementary text and tables S8 and S9).
Exclusion of any single variable from the DETECT algorithm
had only a small impact on model performance (see online sup-
plementary text and table S11). If more than one variable is
missing, the model cannot be used reliably; in clinical practice, a
single missing variable should be handled as described in the
legend to ﬁgure 3. Depending on the risk points in Step 1 of the
algorithm, Step 2 (echocardiography) may not be needed for
recommending RHC in some patients (ﬁgure 3).
As presented in table 3, the rate of missed PAH diagnoses was
4% (n=3) applying the DETECT algorithm. The three missed
PAH patients had mPAP values of 26, 25 and 30 mm Hg,
PCWP values of 11–12 mm Hg, PVR values of 238–
257 dyn·sec/cm5, TR velocities of 2.9, 2.5 and 2.6 m/s, RA areas
of 16.4, 15.0 and 8.5 cm2, NTproBNP levels of 204, 47 and
71 pg/ml, no right axis deviation on ECG, and were ACA nega-
tive. The 4% missed diagnoses rate of the DETECT algorithm
compares with 29% (n=24; see patient characteristics in online
supplementary table S7) based on current ESC/ERS guidelines.1
The proportion of RHC which did not conﬁrm a diagnosis of
PAH was similar between the DETECT algorithm and the ESC/
ERS guidelines (65% vs 60%). Applying the DETECTalgorithm
recommended referral of 62% of patients to RHC. Reducing
the RHC referral rate from 62% to 41% (ie, to a similar level as
the 40% RHC referral rate observed with the ESC/ERS guide-
lines) increased the rate of missed PAH diagnoses to 15%
(n=11) which is still lower than the 29% achieved with the
ESC/ERS guidelines (table 3).
Among the 466 patients who underwent RHC, one patient
had a haematoma caused by accidental carotid puncture. This
was managed without hospital admission or transfusion.
DISCUSSION
DETECT was a large, multicentre, real-world, cross-sectional
study with detailed population characterisation, standardised
RHC and echocardiography procedures, central serum testing,
central data management and rigorous data monitoring. It is the
ﬁrst PAH detection study to undertake systematic RHC in all
patients and to develop an evidence-based algorithm using
simple clinical data and non-invasive tests for earlier identiﬁca-
tion of PAH in a mildly symptomatic population. The DETECT
study demonstrates that within this cohort of SSc patients, PAH
is much more common than previous studies have suggested,21 22
Table 2 Logistic regression models
Univariable logistic regression models* Multivariable logistic regression models (two-step decision tree)
ROC AUC,% (95% CI) Estimated coefficient (95% CI) p value ROC AUC,% (95% CI)
Step 1 84.4 (79.5 to 89.8)
Intercept −12.488 (−16.372 to −8.603)
FVC % pred./DLCO % pred. 71.5 (65.6 to 77.4) 1.149 (0.566 to 1.731) <0.001
Current/past telangiectasias 59.7 (55.4 to 64.1) 1.156 (0.336 to 1.975) 0.006
Serum ACA (presence) 62.4 (56.4 to 68.4) 0.753 (0.133 to 1.373) 0.017
Serum NTproBNP (log10) 67.5 (60.9 to 74.2) 0.915 (0.308 to 1.521) 0.003
Serum urate 71.9 (65.9 to 77.9) 1.247 (0.497 to 1.997) <0.001
Serum urate (spline component†) −1.132 (−2.048 to −0.215) –
Right axis deviation (presence) 54.9 (51.1 to 58.7) 1.850 (0.507 to 3.193) 0.007
Step 2 88.1 (82.4 to 92.3)
Intercept −2.452 (−5.747 to 0.844)
Linear predictor Step 1 0.891 (0.559 to 1.224) <0.001
Right atrium area‡ 71.2 (65.0 to 77.3) 0.075 (−0.004 to 0.154) 0.062
TR velocity 79.5 (73.7 to 85.3) 0.209 (−1.117 to 1.534) <0.001
TR velocity (spline component†) 2.656 (0.380 to 4.933) –
*The ROC AUC values of the corresponding univariable logistic regression models are added for the sake of comparison.
†Serum urate and TR velocity were included in the respective models using restricted cubic splines with three knots. Knots for serum urate were selected at 3.3, 4.7 and
7.1 mg/100 ml and for TR velocity were selected at 2, 2.5 and 3.4 m/s. For each of these two variables only one p value is presented indicating its overall effect.
‡When right ventricle area was used instead of right atrium area, the p value was 0.035; the rest of the p values remained with similar results.
ACA, anticentromere antibody; DLCO, pulmonary diffusing capacity for carbon monoxide; FVC, forced vital capacity; NTproBNP, N-terminal probrain natriuretic peptide; ROC AUC, area
under the receiver operating characteristic curve; TR, tricuspid regurgitant jet.
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Figure 2 Two-step decision tree for detection of pulmonary arterial hypertension in systemic sclerosis patients: the DETECT algorithm. Of the 408
SSc patients (87 PAH and 321 non-PH) at risk for PAH (SSc of >3 years’ duration, DLCO <60% of predicted, FVC ≥40% of predicted), data from 319
patients (72 PAH and 247 non-PH) were used for construction of the algorithm. All patients underwent right heart catheterisation. Sensitivity and
speciﬁcity of the two steps of the algorithm (and the corresponding risk point cut-offs) were selected by the Study Scientiﬁc Committee with the aim
of minimising the number of missed PAH diagnoses. Step 1: A complete dataset was available for 356 patients. The combined discriminatory ability
of the six selected non-echocardiographic variables expressed as the AUC of the ROC curve was 84.4% (95% CI 79.5% to 89.8%) showing good
discriminatory performance and no statistically signiﬁcant lack of ﬁt (see online supplementary appendix 5). At Step 1, a predeﬁned sensitivity
cut-off of 97% (corresponding to >300 risk points, compare ﬁgure 3), determined no referral to echocardiography in 52 patients. Among these, 50
were true negatives (patients without PAH on right heart catheterisation) and two were false negatives (PAH conﬁrmed on right heart
catheterisation). Step 2: A complete dataset was available for 267 patients. The AUC of the ROC curve for the total risk points from Step 1, plus the
two selected echocardiographic variables, was 88.1% (95% CI 82.4% to 92.3%). A predeﬁned speciﬁcity cut-off of 35% (corresponding to >35 risk
points, compare ﬁgure 3), determined no referral to right heart catheterisation in 69 patients. Among these, 68 were true negatives and one was a
false negative. Right heart catheterisation in the remaining 198 patients yielded 69 true positives (PAH conﬁrmed) and 129 false positives. Thus,
overall, the algorithm missed 3 (4%) out of the 72 PAH patients who had sufﬁcient data to be included in the analysis. Note that the algorithm
uses cut-offs for the risk points of the two steps only but not for individual parameters. ACA, anticentromere antibody; AUC, area under the curve;
DLCO, pulmonary diffusing capacity for carbon monoxide; FVC, forced vital capacity; NTproBNP, N-terminal probrain natriuretic peptide; PAH,
pulmonary arterial hypertension; PH, pulmonary hypertension; ROC, receiver operating characteristic; SSc, systemic sclerosis; TR, tricuspid regurgitant
jet.
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and can be identiﬁed before symptoms are sufﬁciently advanced
to be discriminated from general SSc symptoms.
Previous screening initiatives21 22 without systematic RHC in
all patients, resulted in guideline recommendations based on
symptoms and echocardiography without information on the
number of missed PAH diagnoses (false negatives).1 2 10
Consequently, PAH continues to be diagnosed late with
advanced symptoms.6 8 23 Given the evidence that early inter-
vention may delay morbidity in PAH,9 and that screening pro-
grammes that allow earlier treatment in patients with PAH
Figure 3 Nomograms for practical application of the DETECT algorithm: determination of the likelihood of pulmonary arterial hypertension and
cut-off points for decision to refer a patient to echocardiography (Step 1) and subsequent right heart catheterisation (Step 2). At Step 1 (top panel),
risk points for each of the six non-echocardiographic variables are calculated by reading from ‘Individual risk points in Step 1’ and adding them up
to obtain a total. If the ‘Total risk points from Step 1’ is >300 (corresponding to a sensitivity of 97% as selected by the Study Scientiﬁc Committee)
the patient is referred to echocardiography. Similarly, at Step 2 (bottom panel), risk points for the carried forward ‘Total risk points from Step 1’ and
the two echocardiographic variables are calculated by reading from the ‘Individual risk points in Step 2’. If the ‘Total risk points from Step 2’ is >35
(corresponding to a speciﬁcity of 35% as selected by the Study Scientiﬁc Committee) the patient is referred to right heart catheterisation.
Alternatively, being less conservative (65% predeﬁned speciﬁcity at Step 2), the patient would be referred to right heart catheterisation if ‘Total risk
points from Step 2’ is >40 (compare table 3 for the performance of these two options). Note that all variables will always contribute risk points
irrespective of the measured value; for example, a negative serum ACA will contribute 50 risk points. Exclusion of any single variable from the
DETECT algorithm has only a small impact on model performance (see online supplementary appendix 9). If a single Step 1 variable is missing it
should be assigned 50 risk points, with the exception of current/past telangiectasias which should be assigned 65 points. If a single Step 2 variable
is missing it should be assigned 10 points. The nomograms cannot be reliably used if more than one variable out of the eight total variables is
missing. ACA, anticentromere antibody; DLCO, pulmonary diffusing capacity for carbon monoxide; FVC, forced vital capacity; NTproBNP, N-terminal
probrain natriuretic peptide; TR, tricuspid regurgitant jet.
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related to SSc may change the way patients are managed and
may thus improve prognosis,8 24 the DETECT algorithm
addresses a major medical need in this patient population.
Among all patient populations at risk for developing PAH, SSc
appears most suitable for screening programmes in terms of
prevalence and feasibility.
To align the DETECT approach with clinical practice where
the rheumatologist may have non-echocardiographic data avail-
able prior to referral to a cardiologist for echocardiography, a
corresponding two-step algorithm was developed. This will
limit echocardiography referral to patients at increased PAH
risk. Of course, the algorithm can also be used if all data includ-
ing echocardiography are available at the same time. Sensitivity
and speciﬁcity of the two steps of the algorithm (and the corre-
sponding risk point cut-offs) were selected by the Study
Scientiﬁc Committee with the aim of minimising the number of
missed PAH diagnoses as compared with the ESC/ERS guide-
lines1 (table 3). Given that the high overall sensitivity (96%)
selected for the DETECT algorithm is associated with reduced
speciﬁcity (48%), the rate of RHC required in the high-risk SSc
population included in DETECT is substantial (62%). However,
the proportion of RHC performed that did not conﬁrm a diag-
nosis of PAH was similar between the DETECT algorithm and
the ESC/ERS guidelines (65% vs 60%). Furthermore, overall
RHC usage when applying the DETECT algorithm in clinical
practice is likely to be lower than when compared with current
guideline recommendations, since the latter are applied to the
general SSc population, without enrichment for high PAH risk.
For pragmatic reasons (sample size, reasonable expected positive
predictive value) and ethical considerations (mandated RHC in
all patients) the DETECT algorithm is designed for application
in a high-risk SSc population (inclusion criteria DLCO <60%
and SSc disease duration >3 years). The prevalence of PAH in
SSc patients with a DLCO ≥60% is not known but may be as
low as 1.2%, sevenfold lower than in patients with a DLCO
<60%.21 Screening these patients would not reduce the rate of
missed PAH diagnoses (4% in DETECT) much further, but
would increase the rate of false positives; the number of RHCs
needed per PAH diagnosis was three in DETECT, but would be
six in a population with 10% prevalence and 11 in a population
with 5% prevalence. In a regularly screened unselected SSc
population, incidence and prevalence of PAH were found to
increase progressively, with onset generally after 3 years of
disease.25 Based on these data, it is likely that few PAH patients
were missed in DETECT as a result of the required minimum
SSc disease duration, and that this criterion contributed to selec-
tion of a high-risk population. It is possible, however, that some
PAH patients with very early SSc and preserved DLCO were
missed.
Adjusting the speciﬁcity of the DETECT algorithm to recom-
mend similar RHC referral rates (in the DETECT high-risk
population) as the ESC/ERS guidelines still substantially reduces
the number of missed PAH diagnoses (table 3). As shown in this
study and in previous published experience,26 RHC is a safe
technique in experienced centres.
Clinical plausibility, feasibility and applicability of the ﬁnal
selected variables were assured by expert input, and their robust-
ness was internally validated. Some parameters previously identi-
ﬁed as predictive of PAH were conﬁrmed in DETECT, such as
FVC/DLCO,27 telangiectasias,27 ACA,27 28 NTproBNP,11 29 right
axis deviation on ECG30 and TR velocity.8 22 Serum urate has not
been described previously as being predictive of PAH, but was
identiﬁed as such in this study where low values were associated
with a low PAH risk. There is, however, some support for an asso-
ciation in the literature; in a study of 228 patients, serum urate
levels were signiﬁcantly higher in those with PAH than in age-
matched controls,31 ﬁndings that have been corroborated else-
where.32 Interestingly, we have demonstrated the limited utility of
the two main components of current guidelines, that is, symptoms
and echocardiography: dyspnoea, a prominent symptom of PAH,
did not discriminate between PAH and absence of PH (which is
consistent with its lack of sensitivity in identifying cardiopulmon-
ary compromise in early disease perhaps due to SSc-associated
restricted musculoskeletal mobility), and TR velocity alone would
have missed 20% of PAH patients when using a PAH suspicion
threshold of ≥2.5 m/s, 36% when using a threshold of >2.8 m/s
and 63% when using a threshold of >3.4 m/s.
An expert consensus on criteria for referring SSc patients to
RHC has been published recently.33 The objectives, methodology
and population of this study were different from those of
DETECT (consensus-based assessment of symptomatic patients
with suspected PH rather than prospective data-driven assess-
ment of a primarily screening population without requirement
for PAH suspicion). Of the criteria proposed by the expert
Table 3 Model performance: comparison of PAH detection approaches
Approach
RHC referral rate, % (positive
detection assessments/all patients)
Overall missed PAH
diagnoses, % (false
negatives)
Overall
sensitivity, %
Overall
specificity, %
Overall
PPV, %
Overall
NPV, %
Primary analysis
DETECT algorithm
N=319
62 4 96 48 35 98
Other analyses
DETECT algorithm with
65% specificity at Step 2
N=319
41 15 85 72 47 94
ESC/ERS guidelines*1
N=371
40 29 71 69 40 89
*Evaluated on a subset of patients (N=371) with available data for the variables defined in the guideline, using the following criteria for RHC referral1: (a) Tricuspid regurgitant jet
velocity >3.4 m/s; or (b) Tricuspid regurgitant jet velocity >2.8–≤3.4 m/s AND symptomatic (defined as at least one of the following DETECT parameters: current anginal pain, current
syncope/near syncope, current dyspnoea, presence of peripheral oedema); or (c) Tricuspid regurgitant jet velocity ≤2.8 m/s AND symptomatic (defined as above) AND presence of
additional echocardiography variables suggestive of pulmonary hypertension (defined as right atrium area >16 cm2 and/or ratio of right ventricular diameter/left ventricular end diastolic
diameter >0.8).
ESC/ERS, European Society of Cardiology/European Respiratory Society; NPV, negative predictive value; PAH, pulmonary arterial hypertension; PPV, positive predictive value (confirmed
PAH out of all RHC referrals); RHC, right heart catheterisation.
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consensus, dyspnoea, physical ﬁndings related to the right heart
and WHO functional class were not sufﬁciently predictive to
proceed to the ﬁnal DETECTalgorithm. DLCO (and DLCO cor-
rected for alveolar volume) was less predictive than FVC/DLCO.
DETECT conﬁrmed the value of TR velocity as one component
of the algorithm despite poor performance as a single parameter.
The predictive value of both RV and RA dilation was conﬁrmed
in DETECT; RA area is part of the ﬁnal algorithm.
The inclusion criteria selected for prevalent SSc patients,
which may have resulted in an over-representation of limited
cutaneous SSc. Additionally, the DETECT algorithm was not
developed to identify other forms of PH; application of the
DETECT algorithm to the total PH population missed 19% of
WHO group 2 PH patients, and 37% of WHO group 3 PH
patients, both of which are common in SSc. The guideline deﬁ-
nitions used for PH classiﬁcation in DETECT do not consider
other variables which may be relevant in clinical practice, for
example, PVR, echocardiographic parameters to identify left
ventricular disease, exercise haemodynamics or ﬂuid challenge
in borderline PH, or elevated transpulmonary gradient that may
have increased risk of progression to PAH.34 Pulmonary
veno-occlusive disease was not considered, since neither system-
atic radiological assessment nor lung biopsy were performed.
Finally, the results are based on cross-sectional analyses; it is not
possible to determine algorithm performance long-term, or to
recommend how frequently patients should be assessed. Results
from this study were not validated externally but internal valid-
ation using well-established methodology (bootstrapping) con-
ﬁrmed that our ﬁndings are robust.
In conclusion, in this cross-sectional multicentre study, we
have addressed the fundamental ﬂaw in all previous screening
studies in PH by mandating diagnostic RHC in all patients and,
thus, determining the false negative rate. The resultant
DETECT algorithm is highly sensitive, reducing missed diagno-
ses when compared with the ESC/ERS guidelines and optimising
resource usage by restricting detection efforts to the appropriate
high-risk population. Evidence-based guideline recommenda-
tions for the identiﬁcation of mildly symptomatic PAH patients
can now be developed, facilitating earlier intervention.
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